Alexion's top brass has hit the exits amid an investigation into sales practices, and Ophthotech's future is in jeopardy following a high-profile phase 3 failure.
News & Analysis: Ophthotech
Ophthotech's future is in jeopardy following a high-profile phase 3 failure.
Shares collapse after the company reports disappointing results from two phase 3 clinical trials.
Ahead of pivotal phase 3 study results for Fovista, hedge-fund icon Steven Cohen's Point72 has reported a 5% ownership stake in Ophthotech.
Shares drop over new concerns regarding the company's lead compound.
Our healthcare contributors think these pharma companies deserve a closer look from investors.
Shares fall in response to bad news from a competing drug's clinical trial.
Building up the sales numbers for a new drug isn't always easy, but these biotechs offer great examples of predictable marketing success.
It's been a rough year for the clinical-stage biotech. Here's a look back at the key events that have contributed to the stock's decline.
Investors in stem cell stocks have been bludgeoned for several years now, and I think the entire space is un-investable.